Table 2.
Relative survival from 1 month to 5 years for adults (ages ≥20 years at AML diagnosis) with diagnostically confirmed first primary AML who were diagnosed 2001–2018 (followed through 2019) and reported to have received initial chemotherapy for AML according to age at diagnosis, race and ethnicity, sex, calendar year period of diagnosis, and AML subgroup/subtype, SEER-17.
| Characteristic | N | Median age |
Relative survival (%) according to time since AML diagnosis |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-month |
1-year |
3-year |
5-year |
||||||||
| Years | (IQR) | % | (95% CI) | % | (95% CI) | % | (95% CI) | % | (95% CI) | ||
| Total | 28,473 | 60 | (47–71) | 89.9 | (89.5–90.2) | 55.8 | (55.2–56.4) | 35.9 | (35.3–36.5) | 31.9 | (31.3–32.5) |
| Age at diagnosis, years | |||||||||||
| 20–39 | 4592 | 31 | (25–35) | 96.1 | (95.5–96.6) | 80.9 | (79.7–82.0) | 63.3 | (61.9–64.8) | 59.1 | (57.6–60.6) |
| 40–59 | 9253 | 51 | (46–56) | 93.3 | (92.8–93.8) | 66.3 | (65.4–67.3) | 46.9 | (45.8–47.9) | 42.6 | (41.5–43.6) |
| 60–74 | 9798 | 67 | (63–70) | 88.3 | (87.7–89.0) | 47.8 | (46.8–48.8) | 25.6 | (24.7–26.5) | 21.0 | (20.1–21.9) |
| 75–84 | 3978 | 78 | (76–81) | 82.2 | (80.9–83.4) | 29.7 | (28.2–31.2) | 8.9 | (7.9–9.9) | 5.6 | (4.7–6.6) |
| ≥85 | 852 | 87 | (86–89) | 71.4 | (68.2–74.4) | 18.5 | (15.8–21.4) | 4.6 | (3.0–6.7) | 2.6 | (1.2–4.8) |
| Race and ethnicity | |||||||||||
| Non-Hispanic | |||||||||||
| White | 19,038 | 63 | (51–72) | 89.1 | (88.6–89.5) | 53.8 | (53.0–54.5) | 34.2 | (33.5–34.9) | 30.0 | (29.3–30.7) |
| Black | 2417 | 55 | (42–66) | 91.3 | (90.1–92.4) | 56.4 | (54.3–58.4) | 34.7 | (32.7–36.7) | 31.7 | (29.7–33.7) |
| Asian or Pacific Islander | 2621 | 58 | (43–70) | 90.8 | (89.6–91.9) | 57.8 | (55.9–59.7) | 36.9 | (35.0–38.9) | 32.8 | (30.9–34.7) |
| Other specified/unspecifieda | 200 | 56 | (42–70) | 89.6 | (84.5–93.2) | 63.5 | (56.3–69.9) | 46.8 | (39.2–54.0) | 46.2 | (38.6–53.4) |
| Hispanic | 4197 | 50 | (36–65) | 91.9 | (91.0–92.7) | 63.4 | (61.9–64.9) | 43.6 | (42.0–45.2) | 39.7 | (38.1–41.3) |
| Sex | |||||||||||
| Males | 15,751 | 61 | (48–71) | 89.3 | (88.8–89.8) | 54.0 | (53.2–54.8) | 33.5 | (32.7–34.3) | 29.4 | (28.6–30.2) |
| Females | 12,722 | 59 | (45–71) | 90.6 | (90.0–91.1) | 58.1 | (57.2–58.9) | 38.9 | (38.0–39.8) | 34.9 | (34.0–35.8) |
| Calendar year of diagnosis | |||||||||||
| 2001–2006 (follow-up 2007) | 8259 | 59 | (45–70) | 88.6 | (87.9–89.3) | 51.1 | (50.0–52.1) | 31.4 | (30.3–32.5) | 27.9 | (26.8–29.0) |
| 2007–2012 (follow-up 2013) | 9480 | 60 | (46–70) | 90.4 | (89.8–91.0) | 56.6 | (55.6–57.6) | 36.2 | (35.2–37.3) | 32.2 | (31.1–33.3) |
| 2013–2018 (follow-up 2019) | 10,734 | 62 | (48–72) | 90.3 | (89.8–90.9) | 58.9 | (57.9–59.8) | 39.3 | (38.3–40.3) | 35.3 | (34.2–36.4) |
| AML subgroup/subtypeb | |||||||||||
| APL | 3141 | 47 | (35–59) | 90.2 | (89.1–91.2) | 85.0 | (83.7–86.2) | 82.1 | (80.6–83.5) | 79.9 | (78.2–81.4) |
| CBF AML | 1085 | 49 | (35–62) | 95.3 | (93.8–96.4) | 76.3 | (73.6–78.8) | 58.7 | (55.5–61.7) | 54.4 | (51.2–57.6) |
| AML t(8;21)(q22;q22) | 597 | 50 | (35–63) | 96.4 | (94.5–97.6) | 73.3 | (69.5–76.7) | 52.6 | (48.3–56.8) | 48.0 | (43.6–52.2) |
| AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) | 488 | 47 | (36–60) | 93.9 | (91.4–95.7) | 79.9 | (76.0–83.3) | 66.1 | (61.4–70.3) | 62.2 | (57.3–66.7) |
| AML with antecedent condition/therapy | 1983 | 67 | (57–74) | 92.6 | (91.4–93.7) | 45.6 | (43.3–47.8) | 19.4 | (17.6–21.3) | 15.5 | (13.8–17.3) |
| AML with myelodysplasia-related changes | 1848 | 67 | (57–75) | 92.3 | (91.0–93.5) | 44.8 | (42.5–47.1) | 19.1 | (17.2–21.0) | 15.3 | (13.6–17.2) |
| All other AML | 22,264 | 62 | (49–72) | 89.3 | (88.9–89.7) | 51.6 | (51.0–52.3) | 29.7 | (29.1–30.4) | 25.4 | (24.8–26.0) |
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CBF, core binding factor; CI, confidence interval; IQR, interquartile range; SEER-17, 17 cancer registry areas of the Surveillance, Epidemiology, and End Results Program.
Includes American Indian/Alaskan Native, other specified race, and unknown race.
For complete list of AML subtypes please refer to Supplementary Table S1.